Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02392156 · ClinicalTrials.gov registry record
Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes
A clinical trial, sponsored by Bioverativ Therapeutics.
- Terminated
- Registry status
- 3
- Enrollment target
NCT02392156 is a clinical trial that was terminated before completion, run by Bioverativ Therapeutics. The registered enrollment target is 3 participants.
The verdict
NCT02392156 was terminated before completion, sponsored by Bioverativ Therapeutics.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the effectiveness of prophylactic treatment with recombinant Factor VIII Fc fusion protein (rFVIIIFc) and recombinant Factor IX Fc fusion protein (rFIXFc) therapy as assessed by patient treatment burden and health economic outcomes while maintaining disease control in males with hemophilia A or B.
Interventions
- BIOLOGICAL rFVIIIFc
- BIOLOGICAL rFIXFc
- DRUG non-Fc FVIII replacement products
- DRUG non-Fc FIX replacement products
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-07 |
| Est. Completion | 2015-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02392156
The ClinicalTrials.gov registry entry for NCT02392156 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bioverativ Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which rFVIIIFc is the first listed.
NCT02392156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02392156 about?
NCT02392156 is a clinical study titled "Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes". The primary objective of the study is to evaluate the effectiveness of prophylactic treatment with recombinant Factor VIII Fc fusion protein (rFVIIIFc) and recombinant Factor IX Fc fusion protein (rFIXFc) therapy as assessed by patient treatment burden and health economic outcomes while maintaining ...
What is the current status of trial NCT02392156?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2015-07. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02392156?
The interventions under investigation include: rFVIIIFc (BIOLOGICAL), rFIXFc (BIOLOGICAL), non-Fc FVIII replacement products (DRUG), non-Fc FIX replacement products (DRUG).
Who is sponsoring clinical trial NCT02392156?
This trial is sponsored by Bioverativ Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.